[1] Saisho Y. SGLT2 Inhibitors:the star in the treatment of type 2 diabetes [J].Diseases,2020,8(2):14.
[2] Jensen J, Omar M, Kistorp C, et al. Effects of empagliflozin on estimated extracellular volume, estimated plasma volume, and measured glomerular filtration rate in patients with heart failure (Empire HF Renal):a prespecified substudy of a double-blind, randomised, placebo-controlled trial[J]. Lancet Diabetes Endocrinol, 2021,9(2):106-116.
[3] Kolb H, Kempf K, Röhling M, et al. Ketone bodies: from enemy to friend and guardian angel[J]. BMC Med, 2021,19(1):313.
[4] Abdul Kadir A, Clarke K, Evans RD. Cardiac ketone body metabolism[J]. Biochim Biophys Acta Mol Basis Dis, 2020,1866(6):165739.
[5] Lopaschuk GD, Karwi QG, Ho KL, et al. Ketone metabolism in the failing heart[J]. Biochim Biophys Acta Mol Cell Biol Lipids, 2020,1865(12):158813.
[6] Yeves AM, Ennis IL. Na+/H+exchanger and cardiac hypertrophy[J]. Hipertens Riesgo Vasc, 2020,37(1):22-32.
[7] Al-Shamasi AA, Elkaffash R, Mohamed M, et al. Crosstalk between sodium-glucose cotransporter inhibitors and sodium-hydrogen exchanger 1 and 3 in cardiometabolic diseases[J]. Int J Mol Sci, 2021,22(23):12677.
[8] Packer M. SGLT2 inhibitors produce cardiorenal benefits by promoting adaptive cellular reprogramming to induce a state of fasting mimicry: a paradigm shift in understanding their mechanism of action[J]. Diabetes Care, 2020,43(3):508-511.
[9] Salvatore T, Caturano A, Galiero R, et al.Cardiovascular benefits from gliflozins: Effects on endothelial function[J]. Biomedicines, 2021,9(10):1356.
[10] Correale M, Mazzeo P, Mallardi A, et al. Switch to SGLT2 inhibitors and improved endothelial function in diabetic patients with chronic heart failure[J]. Cardiovasc Drugs Ther, 2021:2021 Sep 14.
[11] Zhang Y, Lin X, Chu Y, et al. Dapagliflozin: a sodium-glucose cotransporter 2 inhibitor, attenuates angiotensin Ⅱ-induced cardiac fibrotic remodeling by regulating TGFβ1/Smad signaling[J]. Cardiovasc Diabetol, 2021,20(1):121.
[12] Singh JSS, Mordi IR, Vickneson K, et al. Dapagliflozin versus placebo on left ventricular remodeling in patients with diabetes and heart failure: the REFORM trial[J]. Diabetes Care, 2020,43(6):1356-1359.
[13] Kaplinsky E.DAPA-HF trial: dapagliflozin evolves from a glucose-lowering agent to a therapy for heart failure[J]. Drugs Context, 2020,9:2019-11-3.
[14] Nassif ME,Windsor SL, Tang F,et al.Dapagliflozin effects on biomarkers, symptoms, and functional status in patients with heart failure with reduced ejection fraction: the DEFINE-HF trial[J]. Circulation, 2019,140(18):1463-1476.
[15] Packer M,Butler J,Filippatos GS,et al. Evaluation of the effect of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR-Reduced trial[J]. Eur J Heart Fail, 2019,21(10):1270-1278.
[16] Santos-Gallego CG,Vargas-Delgado AP, Requena-Ibanez JA, et al.Randomized trial of empagliflozin in nondiabetic patients with heart failure and reduced ejection fraction[J]. J Am Coll Cardiol, 2021,77(3):243-255.
[17] Anker SD,Butler J,Filippatos GS,et al.Evaluation of the effects of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR-Preserved Trial[J]. Eur J Heart Fail, 2019,21(10):1279-1287.
[18] Nassif ME, Windsor SL, Borlaug BA,et al.The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial[J].Nat Med,2021,27(11):1954-1960.
[19] Bhatt DL,Szarek M, Steg PG,et al. Sotagliflozin in patients with diabetes and recent worsening heart failure[J]. N Engl J Med, 2021,384(2):117-128.
[20] Qiu M, Ding LL, Zhang M, et al. Safety of four SGLT2 inhibitors in three chronic diseases: a meta-analysis of large randomized trials of SGLT2 inhibitors[J]. Diab Vasc Dis Res, 2021,18(2):14791641211011016.
[21] Butler J, Usman MS, Khan MS, et al. Efficacy and safety of SGLT2 inhibitors in heart failure: systematic review and meta-analysis[J]. ESC Heart Fail, 2020,7(6):3298-3309.
[22] Douros A, Lix LM, Fralick M, et al. Sodium-glucose cotransporter-2 inhibitors and the risk for diabetic ketoacidosis: a multicenter cohort study[J]. Ann Intern Med, 2020,173(6):417-425.
[23] Shi N, Shi Y, Xu J, et al. SGLT-2i and risk of malignancy in type 2 diabetes: a meta-analysis of randomized controlled trials[J]. Front Public Health, 2021,9:668368.
[24] Zhuo M, Hawley CE, Paik JM,et al. Association of sodium-glucose cotransporter-2 inhibitors with fracture risk in older adults with type 2 diabetes[J]. JAMA Netw Open, 2021,4(10):e2130762.
[25] Lin C, Zhu X, Cai X, et al. SGLT2 inhibitors and lower limb complications: an updated meta-analysis[J]. Cardiovasc Diabetol, 2021,20(1):91.
[26] Thong KY,Yadagiri M,Barnes DJ,et al. Clinical risk factors predicting genital fungal infections with sodium-glucose cotransporter 2 inhibitor treatment: the ABCD nationwide dapagliflozin audit[J]. Prim Care Diabetes, 2018,12(1):45-50.
